Michael Bröker, Brian Cooper, Lisa M DeTora, Jeffrey J StoddardGlobal Medical Affairs, Novartis Vaccines and Diagnostics, Marburg, Germany, and Cambridge, MA, USAAbstract: Worldwide, invasive meningococcal disease affects about 500,000 people ...
Bröker M+3 more
doaj
Safety, Reactogenicity, and Immunogenicity of a Tetravalent Meningococcal Polysaccharide–Diphtheria Toxoid Conjugate Vaccine Given to Healthy Adults [PDF]
James Campbell+5 more
openalex +1 more source
Meningococcal vaccines and protein-energy undernutrition in children in the African meningitis belt. [PDF]
Sundaram ME+6 more
europepmc +1 more source
A Glycoconjugate Vaccine forNeisseria meningitidisInduces Antibodies in Human Infants That Afford Protection against Meningococcal Bacteremia in a Neonate Rat Challenge Model [PDF]
Kenneth T. Mountzouros+4 more
openalex +1 more source
Active Hospital Based Surveillance for Meningococcal Vaccine Adverse Events after a Community Mass Immunization Program [PDF]
W Vaudry, BE Lee, Adam Roth
openalex +1 more source
Economic evaluation of meningococcal vaccines: considerations for the future. [PDF]
Christensen H+17 more
europepmc +1 more source
Meningococcal Disease among United States Military Service Members in Relation to Routine Uses of Vaccines with Different Serogroup‐Specific Components, 1964–1998 [PDF]
John F. Brundage+3 more
openalex +1 more source
NEW FORMULATIONS: Meningococcal C polysaccharide conjugate vaccine [PDF]
openalex +1 more source